Objective. Th e aim of the present study was to determine the irisin levels in patients with the type 1 diabetes mellitus (T1DM) and to examine the relation of irisin levels with the infl ammation and autoimmunity.
Irisin, being discovered in 2012, is a myokine, synthesized majorly in the skeletal muscle (Bostrom et al. 2012) . Although according to recent studies, the primary factor aff ecting the synthesis of irisin is considered to be exercise, diff erent mechanisms may play a role in the synthesis of irisin. Aft er exercising, the synthesis of fi bronectin type III domain containing 5 (FNDC5) increases in the skeletal muscle with the activation of peroxisome proliferator-activated receptor γ (PPARγ) coactivator 1α. Th en FNDC5 is broken down to irisin, majorly in the skeletal muscle, with an unknown protease enzyme (Ates et al. 2016; Aydin 2014) . Irisin turns the white adipose tissue to brown one and causes thermogenesis (Bostrom et al. 2012) . White adipose tissue contains triglyceride and fatty acid as well as a small amount of mitochondria (De Naeyer et al. 2011) . Brown adipose tissue contains more mitochondria compared to white adipose tissue (Enerback 2010) . Th erefore, while white adipose tissue acts as a lipid storage, brown adipose tissue plays a role in the energy expenditure. Th e uncoupling protein-1 (UCP-1), found in the mitochondria of brown adipose tissue that increases with the eff ect of irisin, causes heat buildup by pumping protons to mitochondrial matrix through the intermembrane space (Jastroch et al. 2010) . Th us, energy consumption increases.
Due to these major eff ects of irisin on the metabolism, many studies have been previously conducted to investigate the association between irisin and metabolic diseases. Irisin levels have oft en been determined to be decreased in the type 2 diabetes mellitus (T2DM) (Choi et al. 2013 ) and increased in obesity (Crujeiras et al. 2014 ) and insulin resistance (Staiger et al. 2013) . It has recently been reported that irisin levels increase in T1DM patients (Espes et al. 2015) . In most of these studies, insulin metabolism has been shown to be eff ective in the variation of irisin levels. We could not fi nd any data indicating how the insulin levels are aff ected by infl ammation and autoimmunity. However, since irisin is a myokine synthesized based on the peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), we think that it is also associated with infl ammation. Because it is known that PGC-1α by increasing the synthesis of proinfl ammatory cytokines may increase the systemic infl ammation at the same time (Handschin 2009) .
Th erefore, we aimed to determine the irisin level in patients with T1DM, in whom both chronic infl ammation and autoimmunity play a role in its etiopathogenesis and to examine the relation of irisin levels with infl ammation and autoimmunity.
Material and Methods
Study population. Th is study was conducted in Ankara Numune Training and Research Hospital (ANEAH), Clinic of Internal Medicine between May and September 2015.
Th e study included a total of 71 adult participants consisting of 35 cases (16 males, 19 females) diagnosed with T1DM and 36 healthy volunteers (15 males, 21 females). T1DM group consisted of patients with documented diagnosis of T1DM, who admitted to our clinic for routine control. Th e healthy control group consisted of voluntary participants who admitted to our hospital for check-up or other reasons, without any known chronic disease and drug use. When cases were being selected for the control group, they were taken respectively, regarding their age, sex, body mass index (BMI) to be similar to patients. BMI was calculated by dividing body dry weight to the square of tall stature in meters (BMI: kg/m 2 ). Participants with known T2DM, documented cardiovascular and cerebrovascular diseases, liver and kidney failure, thyroid disorders, malignancy, infl ammatory diseases related to rheumatism or infections, malnutrition, morbid obesity, smoking, alcohol and drug consumption and those doing regular exercises were excluded from the study. Also patients with high (>100 mg/dl) fasting blood glucose (FBG) in the control group were excluded.
Th is study was designed in accordance with the Helsinki Declaration and approved by the Research Ethics Committee of ANEAH. All participants provided written informed consent.
Biochemical parameters. To determine the irisin levels of all participants who were included in the study, venous blood samples were drawn between 08:00-10:00 a.m. aft er 8 h of fasting. Aft er blood samples were swift ly centrifuged 4000 rpm for 10 min, plasma was separated and serum samples were stored at -80 °C. Th en in all samples, the irisin levels were studied in the same session.
Fasting blood glucose and creatinine were measured with enzymatic colorimetric method, C-reactive protein (CRP) by immunoturbidimetric method, C-peptide level with chemiluminescence immunoassay method in Hitachi Modular P800 auto analyzer (Roche Diagnostic Corp. Indianapolis, Indiana, USA). Glycosylated hemoglobin (HbA1c) was measured with cation exchange high-performance liquid chromatography method by using Arkray ADAMS A1c HA8180 A1c automatic glycohemoglobin analyzer (Arkray Global Business, Inc., Kyoto. Japans).
Serum irisin levels were measured by commercial ELISA kit (EASTBIOPHARM, Hangzhou Eastbiopharm Co. Ltd. China, REF: CK-E90905, LOT: 201,402). Intra-study CV% <10 and inter-study %CV <12.
Anti-glutamic acid decarboxylase (anti-GAD), islet cell antibody (ICA), insulin autoantibody levels of the patients were measured at the time when they were included in the study and were recorded from the patient fi les. Anti-GAD, ICA and insulin autoantibody levels were measured with a Cobas e 601 autoanalyzer (Catolog No. 11731459124, 03051986192, 1173129724, Roche Diagnostics, Mannhaim, Germany) Table 1 summarizes the demographic characteristics and laboratory fi ndings of study population. Sex distribution (p=0.813), mean age (p=0.732) and BMI (p=0.492) levels were similar in both groups. Th e mean age of the women in T1DM group was higher than that of men (36.8 years vs. 21.5 years, p<0.05, respectively). Th e median duration of diabetes in T1DM patients were 3 years. Median HbA1c (81 mmol/mol vs. 30 mmol/mol, p<0.001, respectively) and FBG (205 mg/dl vs. 89 mg/dl, p<0.001, respectively) levels were higher in T1DM patients compared to the control group. While median creatinine levels were similar between the two groups, CRP levels (3.4±0.8 mg/l vs. 1.2±0.6 mg/l, p<0.001, respectively) were higher in the patient group. In T1DM group, the median irisin level (6.8 ng/ml vs. 4.8 ng/ml, p=0.022, respectively) was higher than in the control group (Figure 1) , the mean C-peptide level (0.4±0.1 ng/ml vs. 1.8±0.1 ng/ml, p<0.001, respectively) was lower compared to the control group.
Results
When irisin levels were examined in T1DM patients according to presence of antibody; they were found higher in anti-GAD (p=0.022) positive and ICA (p=0.044) positive groups compared to negative groups. As for IAA group, there was no signifi cant change in irisin levels based on antibody presence (p=0.674) ( Table 2 ). When irisin levels were examined according to sex distribution, similar levels between the male and female groups were obtained (p>0.05).
In Table 3 , the parameters associated with irisin levels are shown in the correlation analysis. In T1DM group irisin levels displayed a positive correlation with HbA1c (r=0.377, p<0.001) and anti-GAD (r=0.392, p=0.020) ( Figure 2 ) and a negative correlation with creatinine (r=-0390, p=0.021). Th ere was no signifi cant relation determined between the other parameters and irisin levels. When the eff ects of age, sex, BMI, and disease duration are cleansed, HbA1c and anti-GAD levels were single risk factors eff ective on the irisin levels while the impact of creatinine level lost its signifi cance.
In the multivariate regression model that included risk factors such as age, sex, BMI, disease duration, HbA1c, FBG, anti-GAD, IAA, creatinine, CRP and C-peptide (B±SE: 17683±2.76, p<0.001), HbA1c and anti-GAD (B±SE: 2.311±0.610, p=0.001) were determined as independent predictors for predicting the irisin levels (Table 4) .
Discussion
In the present study, irisin levels were determined higher in the T1DM patients compared to the control group. In anti-GAD and ICA positive patients, irisin levels were found higher than in negative patients. Irisin levels displayed a positive correlation with HbA1c and anti-GAD in T1DM patients. In multivariable regression analysis, HbA1c and anti-GAD were determined to independent risk factors for irisin levels. Th is is the fi rst study examining the relation of irisin levels with autoimmunity in T1DM patients.
Irisin is a recently discovered myokine that is thought to be associated with the metabolic diseases. While at the beginning, it was considered to be a hormone that can only be synthesized in skeletal muscle, it was later found to be synthesized in many tissues in the body (Huh et al. 2012) . It is believed to be primarily associated with the exercises. It shows its eff ects by infl uencing UCP-1's found in the mitochondria of adipose tissue. UCP-1 increases heat generation by pumping protons coming from the electron transport chain to mitochondrial matrix through intermembrane space and blocking the formation of adenosine triphosphate (Aff ourtit et al. 2012) . With these mechanisms, irisin hormone appeared to be anti-obesity hormone. Indeed, the studies conducted later have determined that irisin levels were higher in the obese patients compared to the healthy control group (Crujeiras et al. 2014) . Th e association between T2DM and iris levels is oft en being questioned in recent studies. Studies have shown that irisin levels were lower in the T2DM patients compared to the control ones (Choi et al. 2013; Moreno-Navarrete et al. 2013; Liu et al. 2014) . In studies conducted with patients with insulin resistance, irisin levels were determined to increase with the insulin resistance and decrease as insulin sensitivity increases (Sesti et al. 2014) . In a study conducted with patients with T1DM, which infl ammation and autoimmunity play a role in its etiopathogenesis, irisin levels were found to be higher compared to the control group (Espes et al. 2015) . In the same study, irisin levels were found to be lower in men compared to women. Considering the results of these studies, it is possible to conclude that irisin hormone is not only associated with exercise, but also with hormones, insulin resistance, infl ammation, and autoimmunity.
In our study, irisin levels were determined higher in the T1DM patients compared to the control ones. Th e data of this study were similar to the other study conducted with T1DM patients. But while irisin levels diff ered according to the sex in the other study, there was no such diff erence determined in our study (Espes et al. 2015) . Th is situation can be explained by the age and BMI. In the other study, BMI levels of women were higher than the men (although not statistically signifi cant). Th e positive correlation between BMI and irisin has been shown in previous studies (Park et al. 2014) . As for its relation with age, the mean age of women in T1DM group of our study was fairly high compared to the other study. Age and irisin levels displayed a negative correlation in the other study (Espes et al. 2015) . Th ese results clarify why irisin levels did not diff er between diff erent sexes in our study.
In the correlation analysis of our study, irisin levels were determined to be negatively correlated with creatinine and positively correlated with HbA1c and anti-GAD. In a previous study conducted with patients with chronic renal failure, irisin levels were determined to be negatively correlated with creatinine (Wen et al. 2013) . Th is case is considered to result from the inhibition of FNDC5, which is the precursor of irisin, by indoxyl sulphate, which is a uremic toxin (Wen et al. 2013 ). We did not found any study examining the relation between irisin and HbA1c in T1DM patients. However, in studies conducted with patients with the T2DM and metabolic syndromein contrast with our study -irisin levels were negatively correlated with HbA1c (Choi et al. 2013; Yan et al. 2014) . Th is relation between irisin and HbA1c have not been interpreted in these studies. Since HbA1c is an indirect indicator of hyperglycemia, the determination of a positive correlation between irisin and HbA1c is not a surprising fi nding. Because previous studies have shown that there is a positive correlation between the blood glucose level and irisin (Liu et al. 2013) . In addition, another study has suggested that Adj R 2 = 0.344. p<0.001* ‡ Age, sex, BMI and disease duration are adjusted Abbreviations: DM -diabetes mellitus; BMI -body mass index; HbA1C -glycosylated hemoglobin A1C; FBG -fasting blood glucose; Anti-GAD -anti-glutamic acid decarboxylase; IAA -insulin auto-antibody; CRP -C-reactive protein irisin increases as a compensatory answer for hyperglycemia (Crujeiras et al. 2014) . Also the determination of HbA1c as an independent risk factor for irisin, in the multivariate regression analysis, supports our thesis.
Th e determination of the high irisin levels in antibody positive patients compared to negative ones and determination of a positive correlation between irisin levels and anti-GAD; suggests that autoimmunity may have a role in the increase of irisin levels. Th e relation between irisin and autoimmunity can be explained as follows: When the PGC-1α levels increase due to exercise or any other cause; a chronic infl ammatory situation may occur at the cellular level, with the increase in the level of cytokines such as IL-6, IL-8 and IL-15 from a pathway (in our study CRP, an indicator of a chronic infl ammation, was determined higher in the patient group) (Pedersen et al. 2003; Febbraio 2007) . With this infl ammation, occurring with the increase in T cell response, both the number and immunogenicity of auto-antibodies that play a role in autoimmune incidents, may increase. PGC-1α, through another pathway, increases FNDC5 level and leads to an increase in irisin release (Aydin 2014) . Th us, both auto-antibody levels and irisin levels may be increased by the PGC-1α activation. So far, our explanations support our results up to the correlation analysis part. However, this situation does not explain why anti-GAD is an independent risk factor for irisin. So we can bring a possible explanation such as: Auto-antibody levels that increase as a result of chronic infl ammation, can lead to the release of current or synthesized irisin molecules in the pancreas by increasing pancreatic B cell destruction. Because in a study in which specifi c irisin antibody has been used to show irisin immunoreactivity in pancreas, irisin has been shown to exist in the center pancreatic cells, periphery of Langerhans islets, and capillary (Aydin 2014) . Moreover, the presence of the irisin in pancreas has been shown in another study (Aydin et al. 2014) . Th is can be an evidence that irisin is synthesized in pancreas and may be increased with the destruction of pancreas.
Th e main limitation of our study is its cross-sectional design and consequently not being able to follow patients to see how irisin levels diff er with the changes in auto-antibody levels.
As a result, unlike other metabolic disorders, higher irisin levels were determined in T1DM patients compared to the control ones. Th is may suggest that factors such as infl ammation and autoimmunity can be eff ective in the synthesis of irisin. To clarify the association between the autoimmunity and irisin levels previously conducted, randomized control studies, with more number of patients and a longer follow-up process, are required.
